Nivo+Gem/Cis Is Durable, Improves Survival in Patients With Lymph Node-Only mUC

First Look With ASCO Daily News presents Dr. Matt Galsky from the Icahn School of Medicine at Mount Sinai on the results of a post hoc analysis of CheckMate-901 on responses to gemcitabine-cisplatin plus nivolumab versus gemcitabine-cisplatin alone in patients with lymph node-only metastatic urothelial carcinoma.
Read the full abstract (Abstract 4509) from the 2024 ASCO Annual Meeting: meetings.asco.org/abstracts-p...
For more on ASCO24, visit dailynews.ascopubs.org/meetin...